SINOVAC BIOTECH LTD. - Common Shares, par value US$0.001 per share (SVA)
CUSIP: P8696W104
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Shares, par value US$0.001 per share
- Shares outstanding
- 71,872,133
- Total 13F shares
- 6,270,749
- Share change
- +7,439
- Total reported value
- $40,853,096
- Price per share
- $6.47
- Number of holders
- 8
- Value change
- +$329,323
- Number of buys
- 2
Quarterly Holders Quick Answers
What is CUSIP P8696W104?
CUSIP P8696W104 identifies SVA - SINOVAC BIOTECH LTD. - Common Shares, par value US$0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP P8696W104:
Top shareholders of SVA - SINOVAC BIOTECH LTD. - Common Shares, par value US$0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Vivo Capital IX, LLC |
13D/G
|
— |
6.3%
|
4,539,456
|
$293,522,587 | $0 | 17 Mar 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
3.8%
|
2,718,735
|
$184,466,170 | — | 30 Sep 2025 | |
| Vivo Capital, LLC |
13F
|
Company |
8.2%
|
5,903,000
|
$38,192,410 | — | 30 Sep 2025 | |
| Neumann Advisory Hong Kong Ltd |
13F
|
Company |
0.44%
|
315,586
|
$2,042,000 | — | 30 Sep 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.02%
|
16,876
|
$109,188 | — | 30 Sep 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.02%
|
16,430
|
$106,302 | — | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.01%
|
9,144
|
$59,161 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0%
|
2,222
|
$14,376 | — | 30 Sep 2025 | |
| Horizon Investments, LLC |
13F
|
Company |
0%
|
52
|
$336 | — | 30 Sep 2025 | |
| 1Globe Capital LLC |
13D/G
|
— |
32%
|
18,515,315
|
— | $0 | 07 Jul 2025 | |
| SAIF Partners IV L.P. |
13D/G
|
— |
15%
|
10,780,820
|
— | $0 | 15 Dec 2025 | |
| Yin Weidong |
13D/G
|
Weidong Yin |
8.8%
|
6,359,500
|
— | $0 | 10 Jul 2025 | |
| Advantech Capital L.P. |
13D/G
|
— |
8.1%
|
5,851,423
|
— | $0 | 08 Jul 2025 | |
| Vivo Capital VIII, LLC |
13D/G
|
Vivo Capital IX, LLC |
6.3%
|
4,541,764
|
— | $0 | 11 Jul 2025 |
Institutional Holders of SINOVAC BIOTECH LTD. - Common Shares, par value US$0.001 per share (SVA) as of Q4 2025
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.